Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease - PubMed (original) (raw)

Comparative Study

Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease

A P Nisbet et al. Neuroscience. 1995 May.

Abstract

Striatal expression of preproenkephalin and preprotachykinin messenger RNA was studied in normal controls and in patients with Parkinson's disease using in situ hybridization histochemistry. In controls, preproenkephalin messenger RNA was expressed in a population of medium-sized neurons of mean cross-sectional area 165 microns 2, accounting for 66% of striatal medium-sized neurons, whereas preprotachykinin messenger RNA was expressed in a population of medium-sized neurons of mean cross-sectional area 204 microns 2 (23% larger than those expressing enkephalin, P < 0.05), accounting for 58% of medium-sized striatal neurons. Much lower levels of both preproenkephalin messenger RNA and preprotachykinin messenger RNA were expressed by large neurons in the globus pallidus and substantia nigra reticulata. In addition, preproenkephalin messenger RNA was expressed at low levels by neurons in the subthalamic nucleus. In Parkinson's disease cases, there was a statistically significant increase in preproenkephalin messenger RNA expression in the body of the caudate (109% increase, P < 0.05) and in the intermediolateral putamen (55% increase, P < 0.05) due to an increase in the level of gene expression per neuron rather than an increase in the number of neurons expressing preproenkephalin messenger RNA. Similar increases were observed in other putaminal subregions and in the putamen as a whole, but these did not reach statistical significance. No change in preprotachykinin messenger RNA expression was detected. These findings demonstrate selective up-regulation of a striatal neuropeptide system in Parkinson's disease compatible with increased activity of the "indirect" striatopallidal pathway, which is thought to play a crucial role in the pathophysiology of akinesia and rigidity in this condition.

PubMed Disclaimer

Cited by

Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Thornton E, Vink R. Thornton E, et al. PLoS One. 2012;7(4):e34138. doi: 10.1371/journal.pone.0034138. Epub 2012 Apr 2. PLoS One. 2012. PMID: 22485158 Free PMC article.
Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.
Barroso-Chinea P, Bezard E. Barroso-Chinea P, et al. Front Neuroanat. 2010 Sep 14;4:131. doi: 10.3389/fnana.2010.00131. eCollection 2010. Front Neuroanat. 2010. PMID: 20890450 Free PMC article.
The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia.
Bartlett MJ, Mabrouk OS, Szabò L, Flores AJ, Parent KL, Bidlack JM, Heien ML, Kennedy RT, Polt R, Sherman SJ, Falk T. Bartlett MJ, et al. Int J Mol Sci. 2020 Dec 22;22(1):20. doi: 10.3390/ijms22010020. Int J Mol Sci. 2020. PMID: 33374986 Free PMC article.
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. Flores AJ, et al. Neuropharmacology. 2018 Oct;141:260-271. doi: 10.1016/j.neuropharm.2018.09.005. Epub 2018 Sep 7. Neuropharmacology. 2018. PMID: 30201210 Free PMC article.

Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease - PubMed (original) (raw)